Osimertinib is approved in nearly 70 countries around the world as the first‐line treatment for patients with locally advanced or metastatic EGFR T790M mutation‐positive NSCLC whose disease has progressed during or after EGFR‐TKI therapy, with objective response rate (ORR) and disease control rate (DCR) approximately at 60% and 90% (Lamb and Scott, 2017; Minari et al., 2016; Stinchcombe, 2016; Tan et al., 2018; Yang et al., 2017; ). This evidence concerns the gene EGFR and non-small cell lung carcinoma.